O

Osmania General Hospital | Department of Nephrology

Research site
(Unclaimed)
Location
3rd Floor, QQDC Building, Afzal Gunj, Hyderabad, Telangana, India
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

13 of 28
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes (SOUL)

The researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease. Participants...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Placebo (semaglutide)

This study is done to see if semaglutide has an effect on walking ability compared with placebo (dummy medicine) in people with peripheral arterial d...

Active, not recruiting
Diabetes Mellitus, Type 2
Peripheral Arterial Disease
Drug: Placebo (semaglutide)
Drug: Semaglutide

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling
Heart Failure
Drug: Placebo
Drug: Ziltivekimab

The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 dia...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Placebo (semaglutide)

This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 s...

Active, not recruiting
Obesity
Drug: Semaglutide
Drug: Placebo semaglutide

This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin icodec take...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: IcoSema
Drug: Insulin icodec

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling
Acute Coronary Syndrome
Other: Placebo
Drug: Milvexian

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivek...

Begins enrollment in 2 months
Acute Myocardial Infarction (AMI)
Cardiovascular Risk
Drug: Placebo
Drug: Ziltivekimab

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA...

Active, not recruiting
Immunoglobulin A Nephropathy
IgA Nephropathy
Drug: Placebo
Drug: Atrasentan

This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non al...

Active, not recruiting
Non-alcoholic Steatohepatitis
Drug: NNC0174 0833 10 mg/mL
Drug: NNC0194 0499 50 mg/mL

The TRACK trial is an investigator-initiated, multicentre, prospective, randomised, quadruple-blind (participant, healthcare provider, data collector...

Enrolling
Chronic Kidney Diseases
Dialysis-dependent Kidney Failure
Drug: Rivaroxaban 2.5 Mg Oral Tablet
Other: Placebo

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Enrolling
Chronic Kidney Disease
Inflammation
Drug: Ziltivekimab C
Drug: Placebo (Ziltivekimab B)

Trial conditions

Diabetes Mellitus (8 trials)
Kidney Diseases (8 trials)
Type 2 Diabetes Mellitus (8 trials)
Chronic Renal Insufficie... (4 trials)
Colitis (3 trials)
IGA Glomerulonephritis (3 trials)
Obesity (3 trials)
Ulcer (3 trials)
Ulcerative Colitis (3 trials)
Cardiovascular Diseases (2 trials)

And 22 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems